Skip to main content
. 2019 Jan 18;20(2):412. doi: 10.3390/ijms20020412

Table 3.

PI3K inhibitors in clinical trial in ALL.

Therapeutic Drug Target (s) Clinical Trial Status Developer Clinical Trial Number
Buparlisib (BKM120) Pan-PI3K inhibitor Phase I Novartis NCT01396499
Dactolisib (BEZ235) PI3K/mTOR inhibitor Phase I Novartis NCT01756118